{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Participants Reporting At Least One AE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Participants Reporting a Severe AE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Participants Reporting a Life-threatening AE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"AE Relation to Drug: Not Related or Probably Not"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"AE Relation to Drug: Possibly Related"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"AE Relation to Drug: Probably or Definitely Relate"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Serious Adverse Events"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"AEs Leading to Discontinuation"}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"description":"Numbers of participants with adverse events (AEs) collected from Day 1 (start of G-CSF Mobilization) to 12 months after transplantation. AEs were reported regardless of relationship to study treatment. The investigator graded each AE using the World Health Organization (WHO) Adverse Event Grading Scale and provided assessments of seriousness and relatedness to study treatment.","groups":[{"description":"Mobilization with Granulocyte Colony Stimulating Factor (G-CSF) (10 µg/kg once a day) for 5 days. Patients received once daily plerixafor treatment (240 mg/kg) in the evening (10 to 11 hours prior to apheresis) for up to 3 days if peripheral blood CD34+ cell counts on Day 5 met the entry criteria. Morning doses of G-CSF (10 µg/kg) continued throughout apheresis.","id":"OG000","title":"All Patients"}],"paramType":"NUMBER","populationDescription":"Safety Population defined as all participants who received G-CSF and/or plerixafor.","reportingStatus":"POSTED","timeFrame":"up to 13 months","title":"Overall Participants Counts of Adverse Events","type":"SECONDARY","unitOfMeasure":"participants"}